Search Result

Results for "

α-synuclein

" in MedChemExpress (MCE) Product Catalog:

By Targets:	α-synuclein (67) Adrenergic Receptor (1) Amyloid-β (7) Apoptosis (2) Autophagy (4) Beclin1 (1) Biochemical Assay Reagents (1) Caspase (1) DNA/RNA Synthesis (2) DYRK (2) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (3) Fungal (2) Isotope-Labeled Compounds (2) Mitochondrial Metabolism (1) Mitophagy (1) Necroptosis (1) NF-κB (1) Nuclear Hormone Receptor 4A/NR4A (1) PINK1/Parkin (1) Proteasome (1) RIP kinase (1) Sirtuin (1) Stearoyl-CoA Desaturase (SCD) (1) Tau Protein (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (3) Endocrinology (1) Infection (2) Inflammation/Immunology (8) Metabolic Disease (2) Neurological Disease (87)

By Targets:

α-synuclein (67)

Adrenergic Receptor (1)

Amyloid-β (7)

Apoptosis (2)

Autophagy (4)

Beclin1 (1)

Biochemical Assay Reagents (1)

Caspase (1)

DNA/RNA Synthesis (2)

DYRK (2)

E3 Ligase Ligand-Linker Conjugates (1)

Endogenous Metabolite (3)

Fungal (2)

Isotope-Labeled Compounds (2)

Mitochondrial Metabolism (1)

Mitophagy (1)

Necroptosis (1)

NF-κB (1)

Nuclear Hormone Receptor 4A/NR4A (1)

PINK1/Parkin (1)

Proteasome (1)

RIP kinase (1)

Sirtuin (1)

Stearoyl-CoA Desaturase (SCD) (1)

Tau Protein (1)

By Research Areas:

Cancer (10)

Cardiovascular Disease (3)

Endocrinology (1)

Infection (2)

Inflammation/Immunology (8)

Metabolic Disease (2)

Neurological Disease (87)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: α-synuclein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P4704A

α-Synuclein (61-95) (human) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-163145

α-Synuclein inhibitor 11	α-synuclein	Neurological Disease
α-Synuclein inhibitor 11 (compound 1) is a selective α-synuclein (α-syn) oligomer formation inhibitor. α-Synuclein inhibitor 11 does not inhibits tau 4R (isoforms 0N4R, 2N4R) or p-tau (isoform 1N4R). α-Synuclein inhibitor 11 can be used for Parkinson's disease (PD) research .

HY-P5082

α-Synuclein 4554W	α-synuclein	Neurological Disease
α-Synuclein 4554W is an inhibitor of *α-Synuclein* (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .

HY-P3140A

α-Synuclein (61-75) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-163519

α-Synuclein inhibitor 13	α-synuclein	Neurological Disease
α-Synuclein inhibitor 13 is an inhibitor of α-synuclein (α-Syn). α-Synuclein inhibitor 13 inhibits the aggregation of α-Syn proteins and is able to break down formed fibers. It is mainly used in Parkinson's disease research .

HY-P4704

α-Synuclein (61-95) (human)	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P3140

α-Synuclein (61-75)	α-synuclein	Neurological Disease
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-P5044

α-Synuclein (45-54) (human)	α-synuclein	Neurological Disease
α-Synuclein (45-54) (human) is the 45-54 fragment of *α-Synuclein. α-Synuclein* is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-P5041

α-Synuclein (34-45) (human)	α-synuclein	Neurological Disease
α-Synuclein (34-45) (human) is the 34-45 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a Parkinson's disease (PD) biomarker .

HY-P5046

α-Synuclein (71-82) (human)	α-synuclein	Neurological Disease
α-Synuclein (71-82) (human) is the 71-82 fragment of *α-Synuclein. α-Synuclein* is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-147668

α-Synuclein inhibitor 6	α-synuclein	Neurological Disease
α-Synuclein inhibitor 6 (compound 3ge) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC₅₀ of 1.70 μM and inhibition ratio at 30 μM of 94.4% .

HY-147666

α-Synuclein inhibitor 4	α-synuclein	Neurological Disease
α-Synuclein inhibitor 4 (compound 3gh) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC₅₀ of 0.98 μM and inhibition ratio at 30 μM of 91.2% .

HY-147669

α-Synuclein inhibitor 7	α-synuclein	Neurological Disease
α-Synuclein inhibitor 7 (compound 3gf) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC₅₀ of 1.95 μM and inhibition ratio at 30 μM of 85.8% .

HY-147667

α-Synuclein inhibitor 5	α-synuclein	Neurological Disease
α-Synuclein inhibitor 5 (compound 4aa) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC₅₀ of 1.22 μM and inhibition ratio at 30 μM of 94.3% .

HY-P5043

α-Synuclein (67-78) (human)	α-synuclein	Neurological Disease
α-Synuclein (67-78) (human) is the 67-78 fragment of *α-Synuclein. α-Synuclein* (67-78) (human) promotes network activity drive and blocks KCl-induced syt1L-ab uptake .

HY-152552

α-Synuclein inhibitor 8	α-synuclein	Neurological Disease
α-Synuclein inhibitor 8 is an active inhibitor of *α-Synuclein* with an IC₅₀ value of 2.5 µM. α-Synuclein inhibitor 8 has highly inhibition on the aggregation and disaggregation of α-Synuclein fibers. α-Synuclein inhibitor 8 reduces the formation of inclusions in neurons that can repairs damage neurons and improves Parkinson’s disease (PD)-like symptoms. α-Synuclein inhibitor 8 has high antioxidant activity and low cytotoxicity .

HY-149509

α-Synuclein inhibitor 9	α-synuclein	Neurological Disease
α-Synuclein inhibitor 9 (Compound 20C) is an *α-Synuclein* inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research. .

HY-147644

α-Synuclein inhibitor 3	α-synuclein	Neurological Disease
α-Synuclein inhibitor 3 (Compound 7g) is a α-synuclein (α -Syn) aggregation inhibitor. α-Synuclein inhibitor 3 can be used for Parkinson’s disease research .

HY-169288

α-Synuclein modulator 1	α-synuclein	Neurological Disease
α-Synuclein modulator 1 (Compound 7k) is a modulator for *α-synuclein. α-Synuclein* modulator 1 exhibits a maximal absorption and emission wavelength of 386 and 603 nm in ACN/PBS (1:1) buffer .

HY-157806

α-Synuclein inhibitor 12	α-synuclein	Neurological Disease
α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of α-Syn (α-synuclein) aggregation and can be used in the study of neurological diseases .

HY-157308

α-Synuclein inhibitor 10	α-synuclein	Neurological Disease
α-Synuclein inhibitor 10 (compound a8) inhibits the activity of α-Syn aggregation with low IC₅₀ value (1.08 μM). α-Synuclein inhibitor 10 exhibits good binding affinity to α-Syn residues. α-Synuclein inhibitor 10 can be used in the research of Parkinson's disease (PD) .

HY-160116

α-Synuclein aggregate binder 1	α-synuclein	Neurological Disease
α-Synuclein aggregate binder 1 (Compound C05-05) is a collective binder and an inhibitor for α-synuclein aggregation. α-Synuclein aggregate binder 1 is utilized in Positron Emission Tomography (PET) imaging and fluorescence microscope, that can diagnose and ameliorate the neurodegenerative disease .

HY-155021

*PROTAC α-synuclein* degrader 5**	α-synuclein	Neurological Disease
PROTAC α-synuclein degrader 5 is a highly selective small-molecule degraders (PROTAC) of *α-synuclein* aggregates, with an DC₅₀ of 7.51 μM and the highest degradation rate D_max of 89%. PROTAC α-synuclein degrader 5 contains probe molecule sery308 and E3 ligase ligands. PROTAC α-synuclein degrader 5 can be used for neurological disease research .

HY-136001

*PROTAC α-synuclein* degrader 3**	α-synuclein	Neurological Disease
PROTAC α-synuclein degrader 3 (Compound 5) is a selective *α-synuclein* PROTAC degrader. PROTAC α-synuclein degrader 3 can promote the ubiquitination and degradation of α-synuclein. PROTAC α-synuclein degrader 3 can be used for Parkinson's disease research .

HY-157839

*PROTAC α-synuclein* degrader 6**	α-synuclein	Neurological Disease
PROTAC α-synuclein degrader 6 (compound T3) is a PROTAC degrader of *α-synuclein* and tau, with EC₅₀ of 1.57 μM and 4.09 μM, respectively. PROTAC α-synuclein degrader 6 plays an important role in neurodegenerative diseases (NDs) research (Blue:ubiquitin E3 ligase cereblon ligand (HY-14658), Black: linker (HY-128803); Pink: Ligand for target protein (HY-151035)) .

HY-144696

*Dyrk1A/α-synuclein-IN-2*	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-2 (Compound b20) is a dual Dyrk1A and α-synuclein aggregation inhibitor with an IC₅₀ of 7.8 µM for α-synuclein. Dyrk1A/α-synuclein-IN-2 has high predictive CNS penetration and neuroprotective effect .

HY-N10306

Sycosterol A	α-synuclein	Neurological Disease
Sycosterol A is a sterol-based α-synuclein (α-syn) inhibitor that targets α-synuclein aggregates and inhibits α-synuclein aggregation. Sycosterol A can be used in the study of anti-neurodegenerative diseases .

HY-156435

*tau Protein/α-synuclein-IN-1*	α-synuclein	Neurological Disease
tau protein/α-synuclein-IN-1 is a dual inhibitor of tau protein and *α-synuclein. tau protein/α-synuclein-IN-1 reduces α-syn inclusions development in M17D neuroblastoma cells. tau protein/α-synuclein*-IN-1 can be used in study Alzheimer’s disease .

HY-144695

*Dyrk1A/α-synuclein-IN-1*	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual Dyrk1A and α-synuclein aggregation inhibitor with IC₅₀ values of 177 nM and 10.5 µM, respectively. Dyrk1A/α-synuclein-IN-1 has high predictive CNS penetration and neuroprotective effect .

HY-P10360

Tat-βsyn-degron	α-synuclein	Neurological Disease
Tat-βsyn-degron is an *α-synuclein* knockdown peptide that effectively degrades α-synuclein protein via the proteasome pathway. Tat-βsyn-degron effectively reduces α-synuclein protein levels in primary rat cortical neuron cultures. In a Parkinson's mouse toxicity model, Tat-βsyn-degron can alleviate parkinsonian toxin-induced neuronal damage and movement disorders .

HY-P99356

Cinpanemab BIIB054; Anti-Alpha-synuclein Reference Antibody (cinpanemab)	α-synuclein	Neurological Disease
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to *α-synuclein*. Cinpanemab can be used for the research of Parkinson's disease .

HY-168647

KAC-50.1	α-synuclein	Neurological Disease
KAC-50.1 is an *α-Synuclein* (α-syn) PET ligand, with a K_D of 35 nM toward site 2 in recombinant α-syn fibrils .

HY-159945

*tau Protein/α-synuclein-IN-2*	α-synuclein	Neurological Disease
Tau Protein/α-synuclein-IN-2 (Compound 14T) is a blood-brain barrier penetrating tau and α-syn inhibitor. Through its thiourea linker structure, Tau Protein/α-synuclein-IN-2 dose-dependently reduces α-syn oligomerization. In biosensor cells, Tau Protein/α-synuclein-IN-2 prevents the seeding effect of tau aggregation. In the M17D neuroblastoma model, Tau Protein/α-synuclein-IN-2 exhibits anti-inclusion effects. Additionally, Tau Protein/α-synuclein-IN-2 reduces Aβ plaque formation. Tau Protein/α-synuclein-IN-2 holds promise for Alzheimer's disease and Parkinson's disease research.

HY-135902

Synucleozid NSC 377363	DNA/RNA Synthesis	Neurological Disease
Synucleozid (NSC 377363) is a potent inhibitor of the SNCA mRNA that encodes α-synuclein protein. Synucleozid selectively targets the *α-synuclein* mRNA 5′ UTR at the designed IRE site, decreases the amount of SNCA mRNA loaded into polysomes and thereby inhibits SNCA translation. Synucleozid has the potential for the investigation of Parkinson’s disease .

HY-135902A

Synucleozid hydrochloride NSC 377363 hydrochloride	DNA/RNA Synthesis	Neurological Disease
Synucleozid hydrochloride (NSC 377363 hydrochloride) is a potent inhibitor of the SNCA mRNA that encodes α-synuclein protein. Synucleozid selectively targets the α-synuclein mRNA 5′ UTR at the designed IRE site, decreases the amount of SNCA mRNA loaded into polysomes and thereby inhibits SNCA translation. Synucleozid has the potential for the investigation of Parkinson’s disease .

HY-P99405

Prasinezumab PRX 002; RG 7935; RO 7046015	α-synuclein	Neurological Disease
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated *α-synuclein*. Prasinezumab has the potential for Parkinson's disease research .

HY-121252

Dopal	α-synuclein	Neurological Disease
Dopal is an aldehyde that can be generated in Parkinson's disease by enzymatic degradation of dopamine. Dopal can generate reactive oxygen species (ROS), and triggers aggregation of *α-synuclein. Dopal elicits α-synuclein* accumulation and hampers α-synuclein clearance in primary neurons .

HY-P10404

PDpep1.3	α-synuclein	Others Neurological Disease
PDpep1.3 is a peptide inhibitor of *α-synuclein* that disrupts the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). As a result, PDpep1.3 restores the degradation function of endosomes and lysosomes, reduces the protein level and aggregation of α-synuclei, and protects dopaminergic neurons from α-synuclei-mediated degeneration. PDpep1.3 can be used to study neurodegenerative diseases and protein-protein interactions .

HY-121252A

Dopal (purity>80%)	α-synuclein	Neurological Disease
Dopal (purity>80%) is an aldehyde that can be generated in Parkinson's disease by enzymatic degradation of dopamine. Dopal (purity>80%) can generate reactive oxygen species (ROS), and triggers aggregation of *α-synuclein. Dopal (purity>80%) elicits α-synuclein* accumulation and hampers α-synuclein clearance in primary neurons .

HY-145580

Minzasolmin UCB0599; (R)-NPT200-11	α-synuclein	Neurological Disease
Minzasolmin is an alpha-synuclein oligomerization inhibitor .

HY-N0901A

Corynoxine B 3 Publications Verification	α-synuclein	Neurological Disease Cancer
Corynoxine B is an alkaloid-based autophagy inducer and *α-synuclein* aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances α-synuclein (α-syn) clearance in Parkinson's disease mice .

HY-130398

Aerophobin-2	α-synuclein	Neurological Disease
Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of *α-synuclein* (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy .

HY-115038

ELN484228	α-synuclein	Neurological Disease
ELN484228 is a blocker of *α-synuclein* which is a key protein in Parkinson’s disease.

HY-122958

Peucedanocoumarin III	α-synuclein	Neurological Disease
Peucedanocoumarin III is an inhibitor of *α-synuclein* and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research .

HY-145580A

(S)-Minzasolmin (S)-UCB0599; (S)-NPT200-11	α-synuclein	Neurological Disease
(S)-Minzasolmin is an isomer of minzasolmin (HY-145580), an inhibitor of α-synuclein oligomerization .

HY-157225

Brazilin-7-acetate	α-synuclein	Metabolic Disease
Brazilin-7-acetate (B-7-A) is an inhibitor of α-synuclein (α-Syn) aggregates. Brazilin-7-acetate inhibits the formation of α-synuclein fibril, mitigates cytotoxicity, and decreases oxidative stress. Brazilin-7-acetate can be used in the research of Parkinson's disease .

HY-N0901AR

Corynoxine B (Standard)	α-synuclein	Neurological Disease Cancer
Corynoxine B Standard is an analytical standard for Corynoxine B. This product is intended for research and analytical applications. Corynoxine B is an alkaloid-type autophagy inducer and *α-synuclein* aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances the clearance of α-synuclein (α-syn) in Parkinson's disease mice .

HY-163613

NS163	α-synuclein	Neurological Disease
NS163 is a *α-Synuclein* aggregation antagonist. NS163 can be used for study of Parkinson’s disease .

HY-169831

HUP-55	α-synuclein	Neurological Disease
HUP-55 is a prolyl endopeptidase inhibitor (IC₅₀ = 5 nM). HUP-55 reduces the dimerization of *α-synuclein* in Neuro2a cells and induces autophagy (Autophagy) in HEK293 cells. It also decreases the increase in reactive oxygen species (ROS) production induced by hydrogen peroxide in SH-SY5Y cells at a concentration of 10 μM. In a mouse Parkinson’s disease model, HUP-55 (10 mg/kg) improves motor function (reduces the use frequency of the impaired paw) and decreases the levels of harmful oligomers of *α-synuclein* in the striatum caused by overexpression of *α-synuclein* .

HY-173049

2N4R Tau/α-Syn against-1	α-synuclein	Neurological Disease
2N4R Tau/α-Syn against-1 (Compound 4d) targets *α-synuclein* and tau protein, inhibits the fibrillation and oligomer formation of α-synuclein and tau proteins, exhibits disaggregation activity on Aβ fibers. 2N4R Tau/α-Syn against-1 can be used in research of Parkinson's disease and Alzheimer's disease .

Cat. No.	Product Name

HY-L085

Anti-Parkinson's Disease Compound Library

1,719 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 1,719 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

Cat. No.	Product Name	Type

HY-D0914

Fast Green FCF

FD&C Green No. 3; Food green 3; C.I. 42053

Dyes

Fast Green FCF is a sea green triarylmethane food dye, with absorption maximum ranging from 622 to 626 nm. Fast Green FCF inhibits α-synuclein aggregation, as well as Aβ and P2X4 receptor, and TLR4/Myd88/NF-κB. Fast Green FCF is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

HY-D0914A

Fast green FCF free acid

Dyes

Fast green FCF free acid is a dye that is acid-resistant. Fast Green FCF free acid inhibits α-synuclein aggregation, as well as Aβ, P2X4 receptor and TLR4/Myd88/NF-κB. Fast Green FCF free acid is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF free acid improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

Cat. No.	Product Name	Target	Research Area

HY-P4704A

α-Synuclein (61-95) (human) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P5082

α-Synuclein 4554W	α-synuclein	Neurological Disease
α-Synuclein 4554W is an inhibitor of *α-Synuclein* (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .

HY-P3140A

α-Synuclein (61-75) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-P4704

α-Synuclein (61-95) (human)	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P3140

α-Synuclein (61-75)	α-synuclein	Neurological Disease
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-P5044

α-Synuclein (45-54) (human)	α-synuclein	Neurological Disease
α-Synuclein (45-54) (human) is the 45-54 fragment of *α-Synuclein. α-Synuclein* is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-P5041

α-Synuclein (34-45) (human)	α-synuclein	Neurological Disease
α-Synuclein (34-45) (human) is the 34-45 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a Parkinson's disease (PD) biomarker .

HY-P5046

α-Synuclein (71-82) (human)	α-synuclein	Neurological Disease
α-Synuclein (71-82) (human) is the 71-82 fragment of *α-Synuclein. α-Synuclein* is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-P5043

α-Synuclein (67-78) (human)	α-synuclein	Neurological Disease
α-Synuclein (67-78) (human) is the 67-78 fragment of *α-Synuclein. α-Synuclein* (67-78) (human) promotes network activity drive and blocks KCl-induced syt1L-ab uptake .

HY-P5106

α-Synuclein (32-37) (human)	Peptides	Others
α-Synuclein (32-37) (human) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P10360

Tat-βsyn-degron	α-synuclein	Neurological Disease
Tat-βsyn-degron is an *α-synuclein* knockdown peptide that effectively degrades α-synuclein protein via the proteasome pathway. Tat-βsyn-degron effectively reduces α-synuclein protein levels in primary rat cortical neuron cultures. In a Parkinson's mouse toxicity model, Tat-βsyn-degron can alleviate parkinsonian toxin-induced neuronal damage and movement disorders .

HY-P10404

PDpep1.3	α-synuclein	Others Neurological Disease
PDpep1.3 is a peptide inhibitor of *α-synuclein* that disrupts the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). As a result, PDpep1.3 restores the degradation function of endosomes and lysosomes, reduces the protein level and aggregation of α-synuclei, and protects dopaminergic neurons from α-synuclei-mediated degeneration. PDpep1.3 can be used to study neurodegenerative diseases and protein-protein interactions .

HY-123485

PPI-1019	Amyloid-β	Neurological Disease
PPI-1019 is an amyloid beta (Aβ) inhibitor. PPI-1019 can be used in the research of neurological diseases and Alzheimer's disease .

Cat. No.	Product Name	Target	Research Area

HY-P99356

Cinpanemab BIIB054; Anti-Alpha-synuclein Reference Antibody (cinpanemab)	α-synuclein	Neurological Disease
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to *α-synuclein*. Cinpanemab can be used for the research of Parkinson's disease .

HY-P99405

Prasinezumab PRX 002; RG 7935; RO 7046015	α-synuclein	Neurological Disease
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated *α-synuclein*. Prasinezumab has the potential for Parkinson's disease research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-121252

Dopal	Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	α-synuclein
Dopal is an aldehyde that can be generated in Parkinson's disease by enzymatic degradation of dopamine. Dopal can generate reactive oxygen species (ROS), and triggers aggregation of *α-synuclein. Dopal elicits α-synuclein* accumulation and hampers α-synuclein clearance in primary neurons .

HY-N0901A

Corynoxine B 3 Publications Verification	Uncaria rhynchophylla (Miq.) Miq. ex Havil. Alkaloids Structural Classification Classification of Application Fields Source classification Rubiaceae Plants Disease Research Fields Indole Alkaloids Cancer	α-synuclein
Corynoxine B is an alkaloid-based autophagy inducer and *α-synuclein* aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances α-synuclein (α-syn) clearance in Parkinson's disease mice .

HY-W042156

Aegeline	Alkaloids Structural Classification Other Alkaloids Source classification Rutaceae Plants Aegle marmelos (L.) Correa	Fungal
Aegeline, a main alkaloid, mimics the yeast SNARE protein Sec22p in suppressing α-synuclein and Bax toxicity in yeast. Aegeline restores growth of yeast cells suppressed by either αsyn or Bax. Antioxidant activity .

HY-W010041

Scyllo-Inositol	Structural Classification Natural Products Source classification Endogenous metabolite	Amyloid-β Endogenous Metabolite
Scyllo-Inositol, an amyloid inhibitor, potentialy inhibits α-synuclein aggregation. Scyllo-Inositol stabilizes a non-fibrillar non-toxic form of amyloid-β peptide (Aβ42) in vitro, reverses cognitive deficits, and reduces synaptic toxicity and lowers amyloid plaques in an Alzheimer's disease mouse model .

HY-107811

Harmol 1 Publications Verification	Neurological Disease Classification of Application Fields Peganum harmala Linn. Source classification Pyridine Alkaloids Plants Endogenous metabolite Indole Alkaloids Alkaloids Monophenols Zygophyllaceae Phenols Disease Research Fields	α-synuclein
Harmol is a TFEB activator, an orally active monoamine oxidase inhibitor that has anti-tumor, anti-depressant, and anti-aging effects. Harmol can induce cell mitosis, autophagy and apoptosis. Harmol promotes the degradation of *α-synuclein* through the regulation of the autophagy-lysosomal pathway, improving motor deficits in mouse models of Parkinson's disease .

HY-N10306

Sycosterol A	Structural Classification Animals Source classification Steroids	α-synuclein
Sycosterol A is a sterol-based α-synuclein (α-syn) inhibitor that targets α-synuclein aggregates and inhibits α-synuclein aggregation. Sycosterol A can be used in the study of anti-neurodegenerative diseases .

HY-130398

Aerophobin-2	Structural Classification Natural Products Marine natural products Source classification Sponge	α-synuclein
Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of *α-synuclein* (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy .

HY-122958

Peucedanocoumarin III	Structural Classification Carpesium cernuum L. Source classification Coumarins Phenylpropanoids Umbelliferae Plants	α-synuclein
Peucedanocoumarin III is an inhibitor of *α-synuclein* and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research .

HY-N0901AR

Corynoxine B (Standard)	Uncaria rhynchophylla (Miq.) Miq. ex Havil. Alkaloids Structural Classification Source classification Rubiaceae Plants Indole Alkaloids	α-synuclein
Corynoxine B Standard is an analytical standard for Corynoxine B. This product is intended for research and analytical applications. Corynoxine B is an alkaloid-type autophagy inducer and *α-synuclein* aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances the clearance of α-synuclein (α-syn) in Parkinson's disease mice .

HY-W042156R

Aegeline (Standard)	Alkaloids Structural Classification Other Alkaloids Source classification Rutaceae Plants Aegle marmelos (L.) Correa	Fungal
Aegeline (Standard) is the analytical standard of Aegeline. This product is intended for research and analytical applications. Aegeline, a main alkaloid, mimics the yeast SNARE protein Sec22p in suppressing α-synuclein and Bax toxicity in yeast. Aegeline restores growth of yeast cells suppressed by either αsyn or Bax. Antioxidant activity .

HY-N1501

Beta-asarone 3 Publications Verification	Acorus tatarinowii Schott Structural Classification Simple Phenylpropanols Araceae Source classification Phenylpropanoids Plants	α-synuclein
Beta-asarone is an orally active and BBB-penatrable anti-inflammatory agent and neuroprotective agent, which is the major ingredient of Acorus tatarinowii Schott. Beta-asarone can protect nerve cells from apoptosis and autophagy, inhibit expression of *α-synuclein*, as well as myocardial protection. Beta-asarone can be used in the study of neurological and cardiovascular diseases .

HY-N0743

Senkyunolide A 2 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Dicerothamnus rhinocerotis Umbelliferae Plants Disease Research Fields Cancer	α-synuclein
Senkyunolide A is a phthalide, anti-tumor cell proliferation agent with anticancer activity. Senkyunolide A protects neurons from corticosterone (HY-B1618)-induced apoptosis by decreasing protein phosphatase PP2A and *α-synuclein* phosphorylation and protein level. Senkyunolide A also inhibits osteoarthritis through the NLRP3 signaling pathway and suppresses the expression of CD137, a diagnostic biomarker for atherosclerosis .

HY-N1501R

Beta-asarone (Standard)	Acorus tatarinowii Schott Structural Classification Simple Phenylpropanols Araceae Source classification Phenylpropanoids Plants	α-synuclein
Beta-asarone (Standard) is the analytical standard of Beta-asarone. This product is intended for research and analytical applications. Beta-asarone is an orally active and BBB-penatrable anti-inflammatory agent and neuroprotective agent, which is the major ingredient of Acorus tatarinowii Schott. Beta-asarone can protect nerve cells from apoptosis and autophagy, inhibit expression of *α-synuclein*, as well as myocardial protection. Beta-asarone can be used in the study of neurological and cardiovascular diseases .

HY-Y0790

Cuminaldehyde p-Isopropylbenzaldehyde	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Rudbeckia laciniata L. Source classification Umbelliferae Plants Endogenous metabolite Disease Research Fields Cancer	α-synuclein
Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC₅₀= 0.00085 mg/mL), α-glucosidase (IC₅₀=0.5 mg/mL) and lipoxygenase (IC₅₀=1370 μM). Cuminaldehyde also inhibits the fibrillation of *α-synuclein* and prevents its aggregation. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .

HY-N2099

Onjisaponin B	Triterpenes Structural Classification Neurological Disease Classification of Application Fields Terpenoids Source classification Polygalaceae Plants Polygala tenuifolia Willd. Disease Research Fields	Autophagy Amyloid-β Caspase NF-κB Apoptosis
Onjisaponin B is an orally active natural product derived from Polygala tenuifolia. Onjisaponin B inhibits NF-κB p65. Onjisaponin B enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin. Onjisaponin B reduces β-amyloid (Aβ) production. Onjisaponin B reduces radiation-induced cell apoptosis. Onjisaponin B has anti-oxidant and anti-inflammatory activities. Onjisaponin B can be used for neurological disease and radiation injury study, and its metabolite tenuifolin (TF) can enter the brain through the BBB .

HY-N0901

Corynoxine 1 Publications Verification	Uncaria rhynchophylla (Miq.) Miq. ex Havil. Alkaloids Source classification Rubiaceae Plants Indole Alkaloids	Autophagy
Corynoxine, a tetracyclic oxindole alkaloid, is isolated from the hooks of Uncaria rhynchophylla. Corynoxine is a natural autophagy enhancer that promotes the clearance of alpha-synuclein via Akt/mTOR pathway .

HY-N0901B

Corynoxine hydrochloride	Uncaria rhynchophylla (Miq.) Miq. ex Havil. Alkaloids Source classification Rubiaceae Plants Indole Alkaloids	Autophagy
Corynoxine hydrochloride, a tetracyclic oxindole alkaloid, is isolated from the hooks of Uncaria macrophylla. Corynoxine hydrochloride is a natural autophagy enhancer that promotes the clearance of alpha-synuclein via Akt/mTOR pathway .

HY-153169

6PPD-Q 1 Publications Verification 6PPD-Quinone	Quinones Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Other Diseases Benzene Quinones Endogenous metabolite Disease Research Fields	α-synuclein
6PPD-Q (6PPD-Quinone) is an environmental pollutant that can be detected in human urine and is widely present in the environment. 6PPD-Q targets and binds to CNR2, CNR1, AA2AR, LCAT, and TRPA1, with CNR2 exhibiting the highest binding affinity, potentially acting as a CNR2 receptor agonist to activate cannabinoid receptors. 6PPD-Q induces intestinal inflammation and barrier damage by disrupting mitochondrial function, reducing neuronal glycolysis metabolites and TCA cycle intermediates, and exacerbating α-synuclein (α-syn) aggregation. 6PPD-Q is applicable in research on environmental toxicology, neurodegenerative diseases, and inflammation-related disorders .

HY-B0528

Octopamine	Structural Classification Monophenols Microorganisms Source classification Phenols	Adrenergic Receptor Endogenous Metabolite
Octopamine is a biogenic monoamine structurally related to noradrenaline, acts as a neurohormone, a neuromodulator and a neurotransmitter in invertebrates. Octopamine can stimulate alpha2-adrenoceptors (ARs) in Chinese hamster ovary cells transfected with human alpha2-ARs. Octopamine increased glycogenolysis, glycolysis, oxygen uptake, gluconeogenesis and the portal perfusion pressure .

HY-Y0790R

Cuminaldehyde (Standard)	Structural Classification Ketones, Aldehydes, Acids Rudbeckia laciniata L. Source classification Umbelliferae Plants Endogenous metabolite	α-synuclein
Cuminaldehyde Standard is the analytical standard of Cuminaldehyde. This product is intended for research and analytical applications. Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC₅₀= 0.00085 mg/mL) and α-glucosidase (IC₅₀=0.5 mg/mL). Cuminaldehyde also inhibits the fibrillation of *α-synuclein* and prevents its aggregation Cuminaldehyde can induce apoptosis in colon adenocarcinoma cells by targeting topoisomerase I and II. In addition, Cuminaldehyde also exerts anti-inflammatory activity by inhibiting lipoxygenase. Cuminaldehyde has a strong inhibitory effect on the growth of Aspergillus flavus and the biosynthesis of aflatoxin B1 (AFB1). Cuminaldehyde can exert anti-injury and anti-neuropathy effects by participating in opioid receptors, L-arginine/NO/cGMP pathways and anti-inflammatory effects. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .

Species:	Human (2) Mouse (1)
Tag:	His (1) Tag Free (2)
Source:	E. coli (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P70660

	SNCA Protein, Mouse Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP; Snca	Mouse	E. coli
	SNCA proteins are critical for synaptic activity and regulate vesicle trafficking and neurotransmitter release. As a monomer, it enhances the vesicle exocytosis process. SNCA Protein, Mouse is the recombinant mouse-derived SNCA protein, expressed by E. coli , with tag free.

HY-P70577

	SNCA Protein, Human Alpha-synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli
	Alpha-synuclein (SNCA) is a key neuronal protein that regulates synaptic activity, including vesicle transport and neurotransmitter release. As a monomer, it enhances vesicle exocytosis, promotes fusion and fusion pore expansion, and increases local Ca(2+) release. SNCA Protein, Human is the recombinant human-derived SNCA protein, expressed by E. coli , with tag free.

HY-P71327

	SNCA Protein, Human (His) Alpha-synuclein; Non-A Beta Component of AD Amyloid; Non-A4 Component of Amyloid Precursor; NACP; SNCA; NACP; PARK1	Human	E. coli
	Alpha-synuclein (SNCA) is a key neuronal protein that regulates synaptic activity, including vesicle transport and neurotransmitter release. As a monomer, it enhances vesicle exocytosis, promotes fusion and fusion pore expansion, and increases local Ca(2+) release. SNCA Protein, Human (His) is the recombinant human-derived SNCA protein, expressed by E. coli , with N-6*His labeled tag. The total length of SNCA Protein, Human (His) is 140 a.a., with molecular weight of ~18.0 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-Y0790S

Cuminaldehyde-d8
Cuminaldehyde-d8 is deuterated labeled Cuminaldehyde (HY-Y0790). Cuminaldehyde is the major component of Cuminum cyminum, a natural aldehyde with inhibitory effect on alpha-synuclein fibrillation and cytotoxicity. Cuminaldehyde shows anticancer activity .

HY-W015307S

4-Ethyloctanoic acid-13C2
4-Ethyloctanoic acid- ¹³C₂ is ¹³C labeled Cuminaldehyde (HY-Y0790). Cuminaldehyde is the major component of Cuminum cyminum, a natural aldehyde with inhibitory effect on alpha-synuclein fibrillation and cytotoxicity. Cuminaldehyde shows anticancer activity .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82328

	alpha Synuclein Antibody (YA2073) SNCA; NACP; PARK1; Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP	WB, IHC-P, IP	Human, Rat
	alpha Synuclein Antibody (YA2073) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2073), targeting alpha Synuclein, with a predicted molecular weight of 14 kDa (observed band size: 18 kDa). alpha Synuclein Antibody (YA2073) can be used for WB, IHC-P, IP experiment in human, rat background.

HY-P81739

	*Phospho-alpha Synuclein* (Ser129) Antibody (YA1484)** SNCA; NACP; PARK1; Alpha-synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP	WB, ICC/IF	Human, Mouse, Rat
	Phospho-alpha Synuclein (Ser129) Antibody (YA1484) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1484), targeting Phospho-alpha Synuclein (Ser129), with a predicted molecular weight of 14 kDa. Phospho-alpha Synuclein (Ser129) Antibody (YA1484) can be used for WB, ICC/IF experiment in human, mouse, rat background.

HY-P83254

	*alpha/beta Synuclein* Antibody (YA2999)** alpha synuclein; beta synuclein; NACP; PD1; SNCA; SNCB	WB, ICC/IF, FC	Human, Mouse, Rat
	alpha/beta Synuclein Antibody (YA2999) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2999), targeting alpha/beta Synuclein, with a predicted molecular weight of 14 kDa (observed band size: 18 kDa). alpha/beta Synuclein Antibody (YA2999) can be used for WB, ICC/IF, FC experiment in human, mouse, rat background.